Levels of H-ras codon 61 CAA to AAA mutation: response to 4-ABP-treatment and Pms2-deficiency

Barbara L Parsons1, Robert R Delongchamp, Frederick A Beland

  • 1Division of Genetic and Reproductive Toxicology, Division of Biometry and Risk Assessment and Division of Biochemical Toxicology, National Center for Toxicological Research, USFDA, Jefferson, AR 72079, USA. bparsons@nctr.fda.gov

Mutagenesis
|November 30, 2005
PubMed

Insights

DNA mismatch repair (MMR) deficiencies do not amplify chemically induced mutations. This study found Pms2-deficient mice did not show a greater mutational response to 4-aminobiphenyl (4-ABP) than MMR-proficient mice.

Area of Science:

  • Genetics
  • Molecular Biology
  • Toxicology

Background:

  • DNA mismatch repair (MMR) deficiencies are linked to increased mutation rates and tumor formation.
  • MMR-proficient mouse models are standard for assessing chemical carcinogenicity.
  • Pms2 is a key protein in the MMR pathway.

Purpose of the Study:

  • To investigate if MMR deficiency enhances chemically induced mutations.
  • To compare the mutational response to 4-aminobiphenyl (4-ABP) in Pms2-deficient versus Pms2-proficient mice.
  • To determine if Pms2 deficiency amplifies H-ras codon 61 mutations.

Main Methods:

  • Utilized Pms2 knockout (Pms2-/-) and wild-type (Pms2+/+) mice.
  • Neonatal mice were treated with 4-aminobiphenyl (4-ABP) or vehicle control.
  • Liver DNA was analyzed for H-ras codon 61 CAA-->AAA mutations using allele-specific competitive blocker-PCR.

Main Results:

  • 4-ABP treatment increased mutant fraction (MF) in both Pms2-proficient and Pms2-deficient mice.
  • The fold-increase in MF from 4-ABP was similar in both genotypes (1.76-fold vs. 1.38-fold).
  • Induced mutation levels were nearly identical between Pms2-proficient and Pms2-deficient mice.

Conclusions:

  • Pms2 deficiency does not amplify the H-ras codon 61 CAA-->AAA mutational response induced by 4-ABP.
  • The study hypothesis that MMR deficiency would amplify chemically induced mutations was not supported for this specific mutation and chemical.
  • Findings suggest MMR status may not universally amplify all chemically induced mutational responses.

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mutations01:39

Mutations

Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life